Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

PubMed

Regulatory Challenges and Opportunities: A Review of U.S. Food and Drug Administration-Approved Artificial Intelligence and Machine Learning-Enabled Cardiovascular Devices.

PMID: 41276747 · 2026

JournalTherapeutic innovation & regulatory science
Year2026
PMID41276747

Abstract

The integration of artificial intelligence (AI) and machine learning (ML) into medical devices has revolutionized healthcare, enhancing diagnostic accuracy and clinical decision-making. However, their rapid evolution poses challenges to traditional regulatory frameworks, particularly in ensuring safety and effectiveness. This review examines current Food and Drug Administration (FDA) regulatory pathways for AI/ML-enabled cardiovascular medical devices. It assesses the pre- and postmarket criteri

Official Source

View on PubMed →

Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.